Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Findings identify Propanc’s PRP as potential strategy to reprogram chemo-resistant pancreatic cancer

Propanc Biopharma (NASDAQ: PPCB) has announced new preclinical research from an academic–industry collaboration from the Universities of Jaén and Granada, led by Dr. Maria Belén Toledo, that has identified the company’s...

October 16, 2026

Executive Moves

Ironwood appoints Tammi Gaskins as CEO

Ironwood Pharmaceuticals (NASDAQ: IRWD) has announced the appointment of chief commercial officer Tammi Gaskins as CEO and a member of the board of directors, effective January 1, 2027. Current CEO Tom McCourt will...

October 16, 2026

Developments

PharmaJet highlights vaccine development opportunities and real-world impact with needle-free delivery at World Vaccine Congress Europe

Closely held PharmaJet has announced its participation in a pre-conference panel at the World Vaccine Conference Europe on October 19, 2026, at 14:15. Entitled From Non-Inferiority to Impact: Accelerating Adoption of...

October 16, 2026

Developments

TIME honors Perimeter’s Claire OCT with special mention on 2026 Best Innovations list

TIME’s Best Innovations of 2026 includes a special mention of Perimeter Medical Imaging AI’s (TSX-V: PINK; OTCQX: PYNKF) Claire OCT System. Claire is the only FDA-approved imaging...

October 15, 2026

Developments

Valion’s next-gen NMR partnership with LarmorBio delivers initial feasibility milestone

Valion Bio (NASDAQ: VBIO) and closely held LarmorBio today announced that Velocity Bioworks, Valion’s wholly owned biologics contract development and manufacturing organization (CDMO) subsidiary, has successfully...

October 15, 2026

Developments

FDA clears Edesa’s IND for Phase 2 vitiligo study

Edesa Biotech (NASDAQ: EDSA) has announced that the FDA has cleared the company’s Investigational New Drug (IND) application for its Phase 2 clinical study of EB06 in vitiligo, enabling Edesa to expand recruitment...

October 15, 2026

Executive Moves

Jennifer Main joins Claritev’s board

Claritev Corporation (NYSE: CTEV) has appointed Jennifer Main as a director of its board of directors, effective today, filling a newly created directorship on the board. Ms. Main brings more than three decades of...

October 15, 2026

Developments

Xenetic and PeriNess report first patient dosed in investigator-led study at TASMC

Xenetic Biosciences (NASDAQ: XBIO) has announced that its collaboration partner, closely held PeriNess, has informed the company that the first patient has been dosed in an investigator-initiated clinical study...

October 15, 2026

Developments

Valion’s Velocity Bioworks capitalizes on domestic CDMO surge amid Section 232 tariffs

Valion Bio (NASDAQ: VBIO) has highlighted the capabilities of its wholly owned contract development and manufacturing organization (CDMO), Velocity Bioworks. Velocity is part of Valion’s own domestic biologics...

October 14, 2026

Developments

Profound’s TULSA abstracts at the 15th iMRI Symposium strengthen real-world evidence, clinical differentiation, and platform expansion opportunity

Profound Medical (NASDAQ:PROF; TSX:PRN) has announced that five abstracts presented at the 15th Interventional MRI (iMRI) Symposium in Boston, Massachusetts, reinforce the growing body of evidence supporting the real...

October 14, 2026

Developments

JWC publishes trial results for Organogenesis’ PuraPly AM in DFUs

Organogenesis Holdings (NASDAQ: ORGO) has announced the publication of peer-reviewed trial results in the Journal of Wound Care (JWC) showing the clinical benefit of PuraPly AM for hard-to-treat diabetic foot ulcers...

October 13, 2026

Developments

USPTO grants Cognition patent for zervimesine through 2045

Cognition Therapeutics (NASDAQ: CGTX) has announced that the United States Patent and Trademark Office (USPTO) has granted a patent covering a novel crystalline form, or polymorph, of zervimesine (CT1812), providing...

October 13, 2026

Subscribe